Here Are My Top 2 No-Brainer Growth Stocks to Buy Now

Intuitive Surgical continues to show durable growth and strong fundamentals with ~85% recurring revenue, $8.4 billion cash at end of Q3 2025, procedure volumes up 20% and revenue up 23% in Q3, a 13% YoY increase in installed base to 10,763 systems and 240 next‑gen da Vinci 5 systems installed in the quarter (vs. 110 a year ago). TransMedics reported Q3 2025 revenue of $143.8 million, up 32% YoY, and earnings of $24.3 million (a 478% YoY increase), holds the only FDA‑approved portable Organ Care System for hearts/lungs/livers, obtained conditional IDE approvals in Aug 2025 for major heart and lung trials beginning Q4 2025, is developing kidney perfusion trials for 2026/27 with commercial launch targeted for 2029, and is expanding logistics via an Italy ground network in partnership with Mercedes‑Benz — all points that could sustain commercial adoption and investor interest in both equities.

Analysis

Market structure: Winners are ISRG (recurring instruments/services; installed base +13% Y/Y to 10,763) and TMDX (OCS logistics + integrated pricing power); hospitals that can afford capex also win while legacy cold-storage suppliers and smaller centers without OCS access lose share. ISRG’s 85% recurring revenue and da Vinci 5 installs (240 in Q3 vs 110 LY) reinforce pricing power; TMDX’s 32% Y/Y revenue and logistics partnerships signal expanding addressable market for high-margin services.

Risk assessment: Tail risks are binary and material — TMDX trial failure (OCS Enhance Heart/Denovo Lung) or adverse CMS/reimbursement changes could erase >50% upside within 12–36 months; ISRG risks include new low-cost entrants and hospital capex freezes. Time horizons: immediate (days) — IV spikes around earnings/trial starts; short-term (weeks–months) — adoption cadence and installations; long-term (years) — market CAGR >14% to 2030 for robotic surgery and OCS commercialization into kidneys (2029 target).

Trade implications: Favor asymmetric exposure — larger core-long to ISRG for cash-flow durability and smaller, optionality-focused exposure to TMDX around trial catalysts. Expect rising option IV on TMDX pre-trial; translate that into calendar/vertical spreads to cap premium. Cross-asset: expect modest compression in ISRG credit spreads, higher equity options vols for TMDX, and localized FX/commodity exposure (fuel) for TransMedics’ logistics ramp.

Contrarian angles: Consensus underestimates hospital capex cyclicality and reimbursement sensitivity — ISRG could underperform if elective surgery growth cools by >10% YoY. Conversely, TMDX may be overhyped vs binary trial outcomes; if OCS trials succeed, adoption curves could be steeper than modeled (50–100% upside over 24–36 months), but position sizing must reflect >30–40% downside risk on failure.

Key Decisions for Investors

• Establish a 2–3% long position in ISRG (NASDAQ: ISRG) as a core holding for 12–24 months; augment with a 12–18 month call spread (buy 10–20% OTM LEAP call, sell 30–40% OTM call) to cap cost while keeping upside exposure. Take profits on +25–35% gains or reassess if global procedure growth falls >10% YoY.
• Initiate a tactical 1–1.5% position in TransMedics (NASDAQ: TMDX) funded by buying Jan 2027 LEAP calls ~20–30% OTM (or a 2–3x call spread) to capture trial upside while capping premium; avoid outright long stock size >2% due to binary trial risk. Trim/exit on negative interim trial signals or if IV-adjusted price rises >50% pre-readout.
• Execute a pair trade: long ISRG (2%) / short a lagging broad medtech ETF (e.g., XLV short 1–1.5%) to express secular robotics premium over capex-sensitive peers; rebalance if spread narrows by >15% or after next ISRG installation release.
• Use options around catalysts: sell short-dated covered calls on ISRG for 2–3% yield if position is held >6 months; on TMDX, prefer calendar or debit verticals to mute pre-trial IV — avoid naked short exposure. Monitor CMS reimbursement notices and TMDX trial enrollment updates in next 30–90 days and adjust sizing if policy shifts or enrollment lags >20% vs plan.